Danish Retail Group Blacklists Cosmetics With PFAS; Australian Animal-Testing Ban; More Cosmetics News

Cosmetics containing fluorinated compounds are no longer welcome in Coop Denmark’s 1,050 stores or its e-commerce platform. Meanwhile, consumer group BEUC proposes changes to the European Cosmetics Regulation to address endocrine-disrupting chemicals, and Australia passes legislation to bar new, cosmetics-only chemicals from market if their safety substantiation relies on animal testing.

3d render of Europe map Earth globe

The leading consumer goods retailer in Denmark, Coop Danmark A/S, announced March 9 that it will no longer be purchasing cosmetic products containing per- and polyfluoroalkyl substances (PFAS), including from international brands, due to concerns about cancer, endocrine disruption and other health risks linked to the ingredient group. (Also see "Personal-Care Ingredient News In Brief: UC Berkeley Study Makes Waves; PFAS In Cosmetics; More" - HBW Insight, 11 December, 2018.) “We have a great focus on protecting our customers from exposure to chemical substances that can contribute to a harmful cocktail effect. By taking the lead, we hope that the entire international beauty industry can be encouraged to find better alternatives,” says Coop Quality Manager Malene Teller Blume. The decision, effective immediately, means that PFAS-containing cosmetics will vanish by mid-September from coop.dk and Coop retail chains – including Kvickly, SuperBrugsen, Dagli’Brugsen and subsidiaries fakta A/S and Irma A/S – which in sum account for 1,050 stores across Denmark and DKK 50bn in annual turnover, according to the release.

European consumer-advocacy group BEUC is convinced that changes are needed to the Cosmetics Regulation in order for endocrine-disrupting chemical (EDC)...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By 

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By 

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.